CytoDyn Provides Updated Pre-Clinical Data Showing Leronlimab (PRO 140) Continues to Suppress Breast Cancer Metastatic Burden >98% Compared with Untreated Animals

Stock Information for CytoDyn Inc

Loading

Please wait while we load your information from QuoteMedia.